−16.50 MUSD
21.84 M
About NLS Pharmaceutics Ltd.
Sector
CEO
Alexander Zwyer
Headquarters
Zurich
Website
Employees (FY)
2
Founded
2015
ISIN
CH0573155204
FIGI
BBG00Y7BVMP3
NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the treatment of neurobehavioral and neurocognitive disorders. Its product portfolio includes Quilience, a treatment for excessive daytime sleepiness and cataplexy associated with narcolepsy; and Nolazol, a treatment for attention deficit hyperactivity disorder. The company was founded by Ronald Hafner, Eric Konofal, and Alexander Zwyer on June 10, 2015 and is headquartered in Zurich, Switzerland.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
